Out with the old. In with the new. Moving beyond Sanger, see how researchers proved that Oxford Nanopore sequencing offers the same accuracy — plus higher throughput, speed & flexibility for routine use. https://lnkd.in/egh3kf4j
Oxford Nanopore Technologies
Biotechnology Research
Our goal is to enable the analysis of anything, by anyone, anywhere.
About us
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
- Website
-
http://www.nanoporetech.com
External link for Oxford Nanopore Technologies
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Oxford
- Type
- Public Company
- Specialties
- DNA sequencing and Next Generation Sequencing
Locations
Employees at Oxford Nanopore Technologies
-
Bruce Ashford
Principal Linux Platform Engineer at Oxford Nanopore Technologies plc
-
Jordan Herman
SVP, General Counsel at Oxford Nanopore Technologies plc
-
Jonathan Ellard
Director, IT Programme Management at Oxford Nanopore Technologies Ltd
-
Andrew G.
“Any sufficiently advanced technology is indistinguishable from magic.”
Updates
-
At #ASHG25, Rosemary Sinclair Dokos described how translational and clinical genetics researchers are using Oxford Nanopore sequencing to explore mechanisms of disease #InOneGo, marking a new era in biological discovery. She also unveiled the PromethION Plus Flow Cell, designed to increase output, enable larger studies, and reduce the cost per genome — expanding access to comprehensive #multiomic analysis. https://lnkd.in/eyXcGYp5
-
-
The Singapore National Precision Medicine (NPM) program is unlocking new insights into genetic diversity. Hear how they are leveraging Oxford Nanopore sequencing to understand the unique genetic variation of this population to enable more precise healthcare and better outcomes for Singapore’s population. Learn more: https://lnkd.in/eM8A2zf4
-
Our abstract submissions for London Calling 2026 are now open! If you’ve been using Oxford Nanopore technology to power the bigger and bolder research questions, we want to hear about it. Submit your abstract here: https://lnkd.in/eCRQfea9 #nanoporeconf
-
On the last day of #ASHG25, make sure to visit booth 619 to discover how not just to get more data, but see how it all connects. Oxford Nanopore sequencing provides seamless insights across multiple dimensions in real-time — in one go. https://lnkd.in/eTDpueqe
-
Oxford Nanopore Technologies reposted this
The Cancer Genomics Consortium (CGC) and Oxford Nanopore Technologies invite you to attend Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing on October 28, 2025. Click here to learn more and to register today: https://buff.ly/qzgD4Bi
-
-
At #ASHG25, discover how adaptive sampling for targeted sequencing is being utilised in #pharmacogenomic and #hereditary cancer panels to deliver rapid, cost-effective, multidimensional insights. Learn how it enriches regions of interest by ejecting irrelevant strands to target only the genes selected - all in real time. https://lnkd.in/eUixFafz
-
What's on at #ASHG25 today? Our industry workshop will explore the next era of biological discovery and teach you how to reveal layers of biology that other technologies leave behind. At our CoLab, discover how to see the bigger picture with Oxford Nanopore sequencing. Learn how you can target difficult-to-sequence regions and resolve repeat-rich areas — on a single platform. Catch our demos at booth 619 to learn how to combine rich #multiomic data with scalable formats and enable new insights into human health and disease. Finally, don’t forget to join our reception to gain the opportunity to learn and network with other members of the Nanopore Community and team, and discover how to unlock multidimensional insights #InOneGo. Find out more: https://lnkd.in/eF_eqjVB
-
Oxford Nanopore Technologies reposted this
If you’re at #ASHG25 come down to booth 619 for 10:15am where I’ll be giving an update on Oxford Nanopore Technologies #EPI2ME - we have coffee and pastries and lots of analysis to talk about!
-
-
Tomorrow, Oxford Nanopore Technologies will share its latest advancements enabling translational and clinical human genetics researchers to uncover deeper insights into disease mechanisms — #InOneGo. Below is a quick snapshot of some of the things we will be talking about at our American Society of Human Genetics (ASHG) 2025 industry session. https://lnkd.in/eThuJMqA